The United States Food and Drug Administration (FDA) has approved Redemplo (plozasiran), providing new hope for adults suffering with familial chylomicronemia syndrome (FCS), one of the world's rarest and most crippling genetic illnesses. The approval, announced today, is a key step in the agency's effort to "bring medications to patients with rare diseases," particularly those who have few or no existing therapeutic alternatives.

FCS substantially impairs the body's capacity to break down triglycerides—fat molecules that circulate in the blood. Because the body cannot metabolise these fats, they are stored in the bloodstream as chylomicrons, which carry fat after meals. Triglyceride (TG) levels in healthy individuals are normally less than 150 mg/dL. Levels above 500 mg/dL are considered significantly high. However, individuals with FCS frequently have TG levels in the thousands, placing them at constant risk of acute pancreatitis, which is a rapid and deadly inflammation of the pancreas. The illness can cause severe abdominal pain, vomiting, and, in some cases, fatal complications. Patients may also develop fatty deposits on the skin called xanthomas. 

FCS affects only 1 to 10 people per million, making study and treatment development difficult. Symptoms start in infancy or childhood. Nonetheless, the FDA's new decision demonstrates that such ultra-rare diseases remain a priority. 

Redemplo is intended to be used in conjunction with a rigorous low-fat diet, with a daily fat limit of 20 grammes. In a year-long clinical trial (NCT05089084), individuals with genetically verified or clinically diagnosed FCS were given either Redemplo or a placebo. Participants received four doses of 25 mg, injected beneath the skin every three months. By month 10, those using Redemplo had a median 59% reduction in fasting triglycerides, compared to the placebo group. These findings point to potentially considerable protection against pancreatitis, one of the disease's most dreaded consequences. 

The injection can be given in the front of the thigh or abdomen, or, if provided by a carer or health practitioner, in the outer upper arm. The most commonly reported side effects are high blood sugar, nausea, headaches, and injection site reactions. 

Redemplo obtained Fast Track, Breakthrough Therapy, and Orphan Drug designations, indicating the severity of the unmet medical need. These regulatory paths are designated for therapies that show promise for serious or uncommon illnesses. 

For patients and families who have long endured limited diets, continual hospitalisation risks, and the emotional toll of an unpredictable illness, the approval represents a long-awaited breakthrough.